<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921180</url>
  </required_header>
  <id_info>
    <org_study_id>950922</org_study_id>
    <nct_id>NCT00921180</nct_id>
  </id_info>
  <brief_title>Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B</brief_title>
  <official_title>Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Positive Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, peginterferon alfa-2a or oral nucleos(t)ides are approved for the treatment with
      HBeAg positive CHB, with the overall HBeAg seroconversion far from satisfactory. Therefore,
      efforts on the various combinations with the currently available drugs are needed to improve
      the overall response rates. The simultaneous combination therapy with oral nucleoside and
      peginterferon alfa-2a from large-scaled randomized trials did not show a superior response
      rate over peginterferon alfa-2a monotherapy. Recently, sequential monotherapy with lamivudine
      for the first 4 weeks, followed by weekly peginterferon alfa-2a has shown favorable HBeAg
      seroconversion rate over peginterferon alfa-2a monotherapy, based on the assumption that
      early viral suppression by lamivudine can restore the immune function to facilitate the later
      immunomodulatory response by peginterferon alfa-2a. With the recent introduction of
      entecavir, the more potent oral nucleoside with few drug resistance, sequential monotherapy
      with entecavir can potently suppress HBV DNA with 4 weeks of treatment, which may facilitate
      the response of peginterferon alfa-2a to achieve HBeAg seroconversion. Therefore, we aimed to
      conduct a placebo controlled randomized control trial to evaluate of adding entecavir early
      in the course of therapy can improve the treatment response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B (CHB) is prevalent in the world, with estimated chronic carriers of 350
      millions worldwide. Currently, peginterferon alfa-2a or oral nucleos(t)ides are approved for
      the treatment with HBeAg positive CHB, with the overall HBeAg seroconversion far from
      satisfactory. Therefore, efforts on the various combinations with the currently available
      drugs are needed to improve the overall response rates. The simultaneous combination therapy
      with oral nucleoside and peginterferon alfa-2a from large-scaled randomized trials did not
      show a superior response rate over peginterferon alfa-2a monotherapy. Recently, sequential
      monotherapy with lamivudine for the first 4 weeks, followed by weekly peginterferon alfa-2a
      has shown favorable HBeAg seroconversion rate over peginterferon alfa-2a monotherapy, based
      on the assumption that early viral suppression by lamivudine can restore the immune function
      to facilitate the later immunomodulatory response by peginterferon alfa-2a. With the recent
      introduction of entecavir, the more potent oral nucleoside with few drug resistance,
      sequential monotherapy with entecavir can potently suppress HBV DNA with 4 weeks of
      treatment, which may facilitate the response of peginterferon alfa-2a to achieve HBeAg
      seroconversion. Therefore, we aimed to conduct a placebo controlled randomized control trial
      to evaluate of adding entecavir early in the course of therapy can improve the treatment
      response.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBeAg seroconversion rate 6 months after the cessation of therapy</measure>
    <time_frame>76 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Entecavir and peginterferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and peginterferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir and peginterferon alfa-2a</intervention_name>
    <description>Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52</description>
    <arm_group_label>Entecavir and peginterferon</arm_group_label>
    <other_name>Entecavir (Baraclude) 0.5 mg/day po at week 1-4</other_name>
    <other_name>Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo and peginterferon</intervention_name>
    <description>Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52</description>
    <arm_group_label>Placebo and peginterferon</arm_group_label>
    <other_name>Placebo 0.5 mg/day po at week 1-4</other_name>
    <other_name>Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis B (presence of HBsAg &gt; 6 months) with HBeAg persistence for more
             than 3 months

          -  Age older than 18 years

          -  HBV DNA &gt; 20,000 IU/mL for more than 2 occasions

          -  Serum ALT levels between 2 to 10 folds the upper limit of normal (ULN)

          -  A liver biopsy compatible with chronic hepatitis B

        Exclusion Criteria:

          -  Anemia (hemoglobin &lt; 13 gram per deciliter for men and &lt; 12 gram per deciliter for
             women)

          -  Neutropenia (neutrophil count &lt;1,500 per cubic milliliter)

          -  Thrombocytopenia (platelet &lt;90,000 per cubic milliliter)

          -  Co-infection with hepatitis B virus (HBV), hepatitis D virus (HDV) or human
             immunodeficiency virus (HIV)

          -  Chronic alcohol abuse (daily consumption &gt; 20 gram per day)

          -  Decompensated liver disease (Child-Pugh class B or C)

          -  Serum creatinine level more than 1.5 times the upper limit of normal

          -  Autoimmune liver disease

          -  Neoplastic disease

          -  An organ transplant

          -  Immunosuppressive therapy

          -  Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases,
             psychiatric diseases, neurological diseases, diabetes mellitus Evidence of drug abuse

          -  Unwilling to have contraception

          -  Known allergic reaction to entecavir or peginterferon alfa-2a

          -  Unwilling to sign inform consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jia-Horng Kao, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shih-Jer Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hosptial, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chih-Lin Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ren-Ai Branch, Taipei City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-Chao Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Far Eastern Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ching-Sheng Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Tzu Chi General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng-Shun Yang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen-Hua Liu, MD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>63572</phone_ext>
    <email>jacque_liu@mail2000.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia-Horng Kao, MD, PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>67307</phone_ext>
    <email>kaojh@ntu.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hosptial, Yun-Lin Branch</name>
      <address>
        <city>Douliou</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Jer Hsu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shih-Jer Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ping-Huei Tseng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chieh-Chang Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Lun Han, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jou-Wei Lin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun-Herng Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Shun Yang, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sheng-Shun Yang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen-Hua Liu, MD</last_name>
      <phone>+886-2-23123456</phone>
      <phone_ext>63572</phone_ext>
      <email>jacque_liu@mail2000.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chen-Hua Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jia-Horng Kao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Jen Liu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Yang Lai, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pei-Jer Chen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ding-Shinn Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Sheng Hsu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ching-Sheng Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Chi Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tai-Chung Tseng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Chao Liang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cheng-Chao Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ren-Ai Branch, Taipei Municipal Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Lin Lin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chih-Lin Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ping-Yeh Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B, chronic</keyword>
  <keyword>Peginterferon alfa-2a</keyword>
  <keyword>Entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

